A toxicological review of beta-adrenergic blockers.
The use of various beta-adrenergic blockers has become extensive as they have been found to be efficacious in the treatment of a number of cardiovascular problems including cardiac arrhythmias, angina pectoris, and hypertension. The widespread and chronic use of these drugs has generated a concern for their potential chronic toxicity. Eighteen beta-adrenergic blockers have been reviewed and the available literature pertaining to their potential carcinogenicity, mutagenicity, and teratogenicity has been summarized and compared.
Jackson
C D
CD
Fishbein
L
L
D000070:Acebutolol / Q000633:toxicity; D000319:Adrenergic beta-Antagonists / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity*; D000526:Alprenolol / Q000633:toxicity; D000818:Animals; D001262:Atenolol / Q000633:toxicity; D003043:Cocarcinogenesis; D004983:Ethanolamines / Q000633:toxicity; D005260:Female; D007700:Kinetics; D007741:Labetalol / Q000633:toxicity; D007928:Lethal Dose 50; D008297:Male; D008790:Metoprolol / Q000633:toxicity; D051379:Mice; D009153:Mutagens; D009248:Nadolol; D009374:Neoplasms, Experimental / Q000139:chemically induced; D010096:Oxprenolol / Q000633:toxicity; D010869:Pindolol / Q000633:toxicity; D011217:Practolol / Q000633:toxicity; D011412:Propanolamines / Q000633:toxicity; D011433:Propranolol / Q000633:toxicity; D051381:Rats; D013015:Sotalol / Q000633:toxicity; D013999:Timolol / Q000633:toxicity
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D009153:Mutagens; D011412:Propanolamines; C017601:pamatolol; D009248:Nadolol; D001262:Atenolol; D010096:Oxprenolol; C025720:primidolol; C028476:Zami 1327; D000070:Acebutolol; C028475:ZAMI 1305; D013999:Timolol; D000526:Alprenolol; D011433:Propranolol; D013015:Sotalol; D010869:Pindolol; C100227:tolamolol; D008790:Metoprolol; D007741:Labetalol; D011217:Practolol